Trial
NCT00520975
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Breast Carcinoma
Intervention
Bevacizumab
Why stopped
Closed early due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-23